Patent intelligence · US
US 10961305
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
Patent details — US 10961305
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 30, 2021
- Expiration
- Mar 25, 2041
- Applicant
- Mereo Biopharma 3 Limited
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 10961305 (Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta) is held by Mereo Biopharma 3 Limited. Status: granted. Granted Mar 30, 2021. Expires Mar 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Mereo Biopharma 3 Limited
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/663, A61K38/22
More from Mereo Biopharma 3 Limited
Related pharmaceutical patents in our USPTO index.
-
US 12173058
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
granted -
US 11701341
Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
granted -
US 11512128
VEGF/DLL4 binding agents and uses thereof
granted -
US 11434204
Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide
granted -
US 11339213
Methods and compositions for treatment of cancer
granted -
US 11234967
Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
granted -
US 11230596
Methods for treatment of cancer comprising TIGIT-binding agents
granted -
US 11136384
Methods for treatment of cancer comprising TIGIT-binding agents
granted
Frequently asked questions
What is US patent 10961305?
US 10961305 (Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta) is held by Mereo Biopharma 3 Limited. Status: granted. Granted Mar 30, 2021. Expires Mar 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10961305?
Mereo Biopharma 3 Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 10961305 expire?
Our index shows an expiration date of Mar 25, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.